Adoptive immune therapy of chemotherapy-refractory CMV-infection with Streptamer-selected T-cells after allogeneic bone marrow- or peripheral blood stem cell transplantation - AIT-CMV-Stage-01

Trial Profile

Adoptive immune therapy of chemotherapy-refractory CMV-infection with Streptamer-selected T-cells after allogeneic bone marrow- or peripheral blood stem cell transplantation - AIT-CMV-Stage-01

Recruiting
Phase of Trial: Phase I/II

Latest Information Update: 29 Aug 2016

At a glance

  • Drugs T cell replacement therapy (Primary)
  • Indications Cytomegalovirus infections; Graft-versus-host disease
  • Focus Adverse reactions
  • Acronyms AIT-CMV-Stage-01
  • Sponsors Stage cell therapeutics
  • Most Recent Events

    • 06 Sep 2011 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top